<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The efficacy of intravenous Nimodipine (used at the rate of 2 mg.h-1) was investigated in the treatment of delayed ischemic deterioration or angiographic vasospasm after <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> caused by a ruptured <z:hpo ids='HP_0002617'>aneurysm</z:hpo> in a randomized, double-blind, placebo-controlled multicenter study </plain></SENT>
<SENT sid="1" pm="."><plain>A total of 127 case reports was validated: 73 patients received Nimodipine, 54 received placebo </plain></SENT>
<SENT sid="2" pm="."><plain>The two groups were comparable in demographic and clinical status data </plain></SENT>
<SENT sid="3" pm="."><plain>Analysis of number of <z:hpo ids='HP_0011420'>deaths</z:hpo> and of patients with severe deficit related to vasospasm alone showed a significant statistical difference (Nimodipine = 19%; Placebo = 49%; p = 0.01) </plain></SENT>
<SENT sid="4" pm="."><plain>The risk of mortality connected with vasospasm was reduced by 82% in the treated group </plain></SENT>
<SENT sid="5" pm="."><plain>Side effects were equally frequent in the two groups </plain></SENT>
<SENT sid="6" pm="."><plain>The only difference noted was the increase in heart rate in group Nimodipine </plain></SENT>
<SENT sid="7" pm="."><plain>The results of this study demonstrate the efficacy of intravenous Nimodipine in the treatment of consequences of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> after a <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> caused by a ruptured <z:hpo ids='HP_0002617'>aneurysm</z:hpo> </plain></SENT>
</text></document>